Polypill

Concept and definition. The polypill is a fixed-dose combination tablet containing several cardiovascular drugs, taken once daily, designed to deliver comprehensive cardiovascular risk reduction in a single pill. The concept was proposed by Wald and Law (BMJ 2003), who calculated that a combination of a statin, three half-dose antihypertensives, aspirin and folic acid given to everyone over 55 could reduce ischaemic heart disease events by about 88% and stroke by about 80%. The rationale is that most cardiovascular risk factors are continuous variables with no threshold, so a fixed low-dose combination benefits a broad population without individual measurement.

Typical composition. A statin (atorvastatin or simvastatin), aspirin 75–100 mg, and two or three antihypertensives at low dose — commonly an ACE inhibitor (ramipril or enalapril), a thiazide-type diuretic and/or a beta-blocker or calcium channel blocker. Folic acid was in the original proposal but has been abandoned, since homocysteine lowering does not reduce events. Secondary-prevention polypills (for patients with established disease) always contain aspirin and a statin; primary-prevention polypills may omit aspirin because its net benefit in primary prevention is now considered unfavourable (ASPREE, ASCEND, ARRIVE).

Advantages — particularly in geriatric and Indian practice. Improved adherence, which is the dominant benefit — reduced pill burden is directly relevant to the polypharmacy of old age. Lower cost, which matters greatly in low-and middle-income settings. Simplified prescribing and dispensing, enabling task-shifting to nurses and community health workers. Wider treatment coverage, closing the large treatment gap in populations where risk factors are undiagnosed. Fewer dispensing and administration errors. India has been central to this field — the TIPS (The Indian Polycap Study) trials, conducted with the Polycap formulation, established the tolerability and risk-factor efficacy of the approach.

Evidence. TIPS-1 and TIPS-2 (India) showed that the Polycap produced the expected reductions in blood pressure, LDL-cholesterol and heart rate with acceptable tolerability. UMPIRE, IMPACT and Kanyini-GAP demonstrated substantially improved adherence compared with usual care. TIPS-3 (NEJM 2021) — a large primary-prevention trial in intermediate-risk people without cardiovascular disease — showed that a polypill plus aspirin reduced major cardiovascular events. SECURE (NEJM 2022) — the key secondary-prevention trial — randomised patients over 65 who had had a recent myocardial infarction to a polypill (aspirin, ramipril, atorvastatin) or usual care and showed a significant reduction in cardiovascular death, myocardial infarction, stroke and urgent revascularisation, driven substantially by better adherence. PolyIran confirmed benefit at a population level in a primary-care setting.

Limitations and criticisms. Loss of individualisation — doses cannot be titrated separately, so it is unsuitable where one component must be adjusted or where the patient is already well controlled on tailored therapy. An adverse effect from one component requires stopping the whole tablet, losing the benefit of the others. Contraindications and interactions — an ACE inhibitor in bilateral renal artery stenosis, a beta-blocker in asthma or severe bradycardia, a diuretic in gout or hyponatraemia, and aspirin where bleeding risk is high. In the older adult the specific risks are hypotension, falls, hyperkalaemia, acute kidney injury, hyponatraemia and gastrointestinal bleeding — so it is generally more appropriate for stable, well-selected secondary prevention than for the frail or newly diagnosed patient. Other issues are medicalisation of healthy populations, uncertainty over the aspirin component in primary prevention, and regulatory and availability limitations in many countries.

In July 2023 the World Health Organization added fixed-dose combination cardiovascular polypills to the WHO Model List of Essential Medicines, for both primary prevention in people at high cardiovascular risk and secondary prevention after an established event. This was a landmark step, based on the SECURE, TIPS-3, PolyIran and UMPIRE evidence, and it reclassifies the polypill from an experimental public-health idea into a recommended, essential therapeutic tool. It is directly relevant to India, where the WHO HEARTS technical package and the national NCD programme promote standardised fixed-dose regimens to close the very large treatment gap in hypertension and secondary prevention. Practical caveat for the examination: current guidance regards the polypill as most clearly indicated for secondary prevention and for high-risk primary prevention in resource-limited settings, not as a substitute for individualised titration in the frail older patient.